Pharmacotherapy for stimulant-related disorders - Test2 - elhamkhani - TriplyDB

Pharmacotherapy for stimulant-related disorders

Pharmacotherapy for stimulant-related disorders

http://www.wikidata.org/entity/Q26829186

about

Clinical potential of methylphenidate in the treatment of cocaine addiction: a review of the current evidence.Assessment of safety, cardiovascular and subjective effects after intravenous cocaine and lofexidine.Effects of buspirone and the dopamine D3 receptor compound PG619 on cocaine and methamphetamine self-administration in rhesus monkeys using a food-drug choice paradigm.Evaluation of the dopamine β-hydroxylase (DβH) inhibitor nepicastat in participants who meet criteria for cocaine use disorder.Safety and Preliminary Efficacy of the Acetylcholinesterase Inhibitor Huperzine A as a Treatment for Cocaine Use Disorder Attenuation of cocaine self-administration by chronic oral phendimetrazine in rhesus monkeys Altered methamphetamine place conditioning in mice vaccinated with a succinyl-methamphetamine-tetanus-toxoid vaccine.

P2860

Q35766564-955D1F6C-941D-4C18-B10B-19CFA261FD45 Q36036175-7F8E54C1-6F6B-46E6-9318-E957E0597A62 Q36581531-AEE87C5B-223E-4DFC-AF30-FA5A72933D5E Q36650526-10AA6918-E111-4100-844A-52F99B3A7611 Q36749831-FD1B142B-86E2-47D7-A9B1-5E73BCB11DD2 Q36818345-868F2D74-3725-45AD-A716-1960DCAD7414 Q50548841-52EA0E71-5253-4449-AD16-B531F58C9DC9

P2860

Pharmacotherapy for stimulant-related disorders

http://www.wikidata.org/entity/Q26829186

description

2013 nî lūn-bûn

@nan

2013 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Pharmacotherapy for stimulant-related disorders

@ast

Pharmacotherapy for stimulant-related disorders

@en

Pharmacotherapy for stimulant-related disorders

@nl

type

label

Pharmacotherapy for stimulant-related disorders

@ast

Pharmacotherapy for stimulant-related disorders

@en

Pharmacotherapy for stimulant-related disorders

@nl

prefLabel

Pharmacotherapy for stimulant-related disorders

@ast

Pharmacotherapy for stimulant-related disorders

@en

Pharmacotherapy for stimulant-related disorders

@nl

P1433

Q26829186-89137629-2AB0-4201-B7DF-213017B3F0A6

P1476

Q26829186-7CE288D1-856A-4192-9DA3-AF24610E8203

P2093

Q26829186-A6424DC8-4F6E-4FCD-A38B-6AAE17503C35

P2860

Q26829186-00A077B3-2DFA-4C5C-8267-79F5A52BD1C5

Q26829186-0109C0C3-310C-475F-ABE2-BD8613D4A741

Q26829186-0254FF15-6B21-4F7D-A44C-D6D5C8F07BFB

Q26829186-05D78E34-3320-4F27-87F5-086E825695F8

Q26829186-0CB6529D-0327-4D6C-9E21-5C05F49152DA

Q26829186-0CFEABE0-D4CD-4B2F-A9AF-7A97D3494671

Q26829186-0EB32F00-A13F-40EB-9EEC-016BD1C920E0

Q26829186-10E209F5-EB94-42BA-A100-B57737319803

Q26829186-13611D7B-FAF6-4A04-ADC0-407441DFB840

Q26829186-13FCB3CC-C949-41AF-A7F7-AA510B2D60F2

P2888

Q26829186-51DF896F-3B40-44DD-8B4B-4825ECB607BF

P304

Q26829186-AA225971-30CA-40AA-A357-3209DF7282F8

P31

Q26829186-0745C672-BC36-45F3-B65D-928B04EC9347

P356

Q26829186-C46EA791-2920-4573-AF21-E19FE842ECAD

P407

Q26829186-99843294-8527-4BE7-9FB6-2E5AA53FA2EB

P433

Q26829186-FEAA19D9-1601-4932-8F95-1B6DECB3CEB2

P478

Q26829186-BB2E8238-773F-4CFD-BD8B-9B77EE0BF788

P50

Q26829186-0BEB06E7-DA0F-48B0-9FD6-F1695E7FFB6A

P577

Q26829186-E8D49834-704D-4DFE-A283-44275219CFD6

P5875

Q26829186-CDC8A430-AF84-4590-A862-B1323834894D

P6179

Q26829186-903343BA-6F09-4888-8FE8-4D6FB44D6DA6

P698

Q26829186-ACFBFC8B-825E-41A1-85D0-BCFCF4D104DF

P921

Q26829186-220043F6-8683-4072-B657-0DA6D3BD7E86

P932

Q26829186-D15380BE-F4EE-44A5-AD1A-15EC98BC60CC

P356

S11920-013-0415-Y

P1433

Current Psychiatry Reports

P1476

Pharmacotherapy for stimulant-related disorders

@en

P2093

Thomas R Kosten

http://www.w3.org/2001/XMLSchema#string

P2860

Effect of modafinil on learning and task-related brain activity in methamphetamine-dependent and healthy individuals

How addictive drugs disrupt presynaptic dopamine neurotransmission

Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications

Methamphetamine toxicity and messengers of death

Modafinil for the treatment of cocaine dependence

Evidence for the involvement of dopamine transporters in behavioral stimulant effects of modafinil

Dysfunction of the prefrontal cortex in addiction: neuroimaging findings and clinical implications.

Abuse liability and safety of oral lisdexamfetamine dimesylate in individuals with a history of stimulant abuse

Lower level of endogenous dopamine in patients with cocaine dependence: findings from PET imaging of D(2)/D(3) receptors following acute dopamine depletion

Differential pharmacokinetics and pharmacodynamics of methylphenidate enantiomers: does chirality matter?

P2888

s11920-013-0415-y

P304

415

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11920-013-0415-Y

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

258061523

http://www.w3.org/2001/XMLSchema#string

P6179

1026125187

http://www.w3.org/2001/XMLSchema#string

P698

24142188

http://www.w3.org/2001/XMLSchema#string

P921

pharmacotherapy

P932

3858902

http://www.w3.org/2001/XMLSchema#string